BioPorto A/S | Balance Sheet

Fiscal year is January-December. All values DKK Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
42,802.00
25,447.00
34,867.00
35,641.00
47,080.00
46,709
Total Accounts Receivable
4,883.00
6,332.00
8,416.00
7,990.00
12,467.00
12,298
Inventories
3,629.00
4,004.00
4,034.00
3,941.00
3,434.00
3,631
Total Current Assets
51,314.00
35,783.00
47,317.00
47,572.00
62,981.00
62,638
Net Property, Plant & Equipment
275.00
612.00
451.00
400.00
263.00
1,437
Total Investments and Advances
253.00
-
-
-
-
-
Intangible Assets
-
199.00
559.00
1,959.00
1,629.00
1,374
Other Assets
-
645.00
666.00
710.00
731.00
752
Total Assets
51,842.00
37,239.00
48,993.00
50,641.00
65,604.00
66,201
ST Debt & Current Portion LT Debt
18.00
18.00
22.00
242.00
182.00
Accounts Payable
961.00
1,199.00
1,227.00
1,169.00
3,412.00
Other Current Liabilities
7,896.00
7,249.00
3,195.00
3,735.00
5,059.00
Total Current Liabilities
8,875.00
8,466.00
4,444.00
5,146.00
8,653.00
Long-Term Debt
105.00
87.00
64.00
40.00
-
Other Liabilities
-
-
-
1,164.00
883.00
Total Liabilities
8,980.00
8,553.00
4,508.00
6,350.00
9,536.00
Common Equity (Total)
42,862.00
28,686.00
44,485.00
44,291.00
56,068.00
Total Shareholders' Equity
42,862.00
28,686.00
44,485.00
44,291.00
56,068.00
Total Equity
42,862.00
28,686.00
44,485.00
44,291.00
56,068.00
Liabilities & Shareholders' Equity
51,842.00
37,239.00
48,993.00
50,641.00
65,604.00

About BioPorto A/S

View Profile
Address
Tuborg Havnevej 15
Hellerup CR 2900
Denmark
Employees -
Website http://www.bioporto.com
Updated 07/08/2019
Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. Its products specialize in coagulation, immunodeficiencies, diabetes, peptide hormones, and kidney diseases. Its portfolio consists of NGAL Test, NGAL ELISA kits, MBL ELISA kits, and AntibodyShop.